A Semi-automated Toolkit for Analysis of Liver Cancer Treatment Response Using Perfusion CT

Abstract Hyperthermia therapy is a promising therapy for liver cancer treatment that utilizes external electromagnetic waves to heat the tumor zone to preferentially kill or minimize cancer cells. Nevertheless, it’s a challenge to realize localized heating of the cancer tissue without harming the surrounding healthy tissue. This research proposes to utilize nanoparticles as microwave absorbers to enhance microwave imaging and achieve localized hyperthermia therapy. A realistic 3D abdomen model has been segmented using 3D Slicer segmentation software, and then the obtained segmented CAD model exported to Computer Simulation Technology (CST STUDIO) for applying the Finite Element Modeling (FEM). Next investigating both imaging and treatment capability. Finally, the specific absorption rate (SAR) and temperature distribution were computed without nanoparticles and with different types of nanoparticles such as gold (GNPs) and silver nanoparticles at frequency 915 MHz. By comparing the achived results, it was seen that Silver nanoparticles can make a great enhancement in raising the temperature. However, this result was unsatisfactory but, after adding gold nanoparticles the temperature exceed 42°C, at frequency 915 MHz which is achieving the hyperthermia treatment without harming the nearby healthy tissue, GNPs also can achieve a great enhancement in SAR result

Download Full-text

Computational approaches to assist in the evaluation of cancer treatment response

Imaging in Medicine ◽

10.2217/iim.11.8 ◽

2011 ◽

Vol 3 (2) ◽

pp. 233-246 ◽

Cited By ~ 2

Author(s):

Mia A Levy ◽

Daniel L Rubin

Keyword(s):

Cancer Treatment ◽

Treatment Response ◽

Computational Approaches

Download Full-text

A Novel 3-D Segmentation Algorithm for Anatomic Liver and Tumor Volume Calculations for Liver Cancer Treatment Planning

10.25148/etd.fi12050223 ◽

2012 ◽

Author(s):

Mohammed Goryawala

Keyword(s):

Liver Cancer ◽

Cancer Treatment ◽

Treatment Planning ◽

Tumor Volume ◽

Segmentation Algorithm ◽

Volume Calculations

Download Full-text

Impact on Liver Cancer Treatment of a First Erroneous Diagnosis of Hemangioma

World Journal of Surgery ◽

10.1007/s00268-014-2643-7 ◽

2014 ◽

Vol 38 (10) ◽

pp. 2685-2691 ◽

Cited By ~ 2

Author(s):

Nazario Portolani ◽

Gianluca Baiocchi ◽

Federico Gheza ◽

Sarah Molfino ◽

Luigi Grazioli ◽

...

Keyword(s):

Liver Cancer ◽

Cancer Treatment ◽

Erroneous Diagnosis

Download Full-text

The Application of Hemoglobin-based Oxygen Carriers in Liver Cancer Treatment in Rodent Models

10.1142/9789811228698_0017 ◽

2021 ◽

pp. 447-460

Author(s):

Xiaobing Liu ◽

Chang Xian Li ◽

Xiang Qi ◽

Bing Lou Wong ◽

Kwan Man

Keyword(s):

Liver Cancer ◽

Cancer Treatment ◽

Rodent Models ◽

Oxygen Carriers

Download Full-text

Phytoactives-loaded nanocarriers for liver cancer treatment

Nanoformulation Strategies for Cancer Treatment ◽

10.1016/b978-0-12-821095-6.00015-x ◽

2021 ◽

pp. 171-191

Author(s):

Mahfoozur Rahman ◽

Kainat Alam ◽

Rafida Ilyas ◽

Sarwar Beg

Keyword(s):

Liver Cancer ◽

Cancer Treatment

Download Full-text

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ◽

10.3727/096504019x15662966719585 ◽

2020 ◽

Vol 28 (1) ◽

pp. 75-94 ◽

Cited By ~ 2

Author(s):

Junhui Sun ◽

Guanhui Zhou ◽

Xiaoxi Xie ◽

Wenjiang Gu ◽

Jing Huang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Liver Cancer ◽

Portal Vein ◽

Treatment Response ◽

Transarterial Chemoembolization ◽

Efficacy And Safety ◽

Portal Vein Invasion ◽

Drug Eluting Beads ◽

Drug Eluting ◽

The Mean

The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response rate (ORR) were 22.9%, 60.7%, and 83.6%, respectively. The mean PFS was 362 (95% CI: 34.9‐375) days, the 6-month PFS rate was 89.4 ± 2.1%, while the mean OS was 380 (95% CI: 370‐389) days, and the 6-month OS rate was 94.4 ± 1.7%. Multivariate logistic regression revealed that portal vein invasion (p = 0.011) was an independent predictor of worse clinical response. Portal vein invasion (p = 0.040), previous cTACE treatment (p = 0.030), as well as abnormal serum creatinine level (BCr) (p = 0.017) were independent factors that predicted worse ORR. In terms of survival, higher Barcelona Clinic Liver Cancer (BCLC) stage (p = 0.029) predicted for worse PFS, and abnormal albumin (ALB) (p = 0.011) and total serum bilirubin (TBIL) (p = 0.009) predicted for worse OS. The number of patients with abnormal albumin, total protein (TP), TBIL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were augmented at 1 week posttreatment and were similar at 1‐3 months compared with baseline. The most common AEs were pain, fever, nausea, and vomiting, and no severe AEs were observed in this study. DEB-TACE was effective and tolerable in treating Chinese HCC patients, and portal vein invasion, previous cTACE treatment, abnormal BCr, ALB, and TBIL appear to be important factors that predict worse clinical outcome.

Download Full-text